TLR3 and Rig-like receptor on myeloid dendritic cells and Rig-like receptor on human NK cells are both mandatory for production of IFN-gamma in response to double-stranded RNA.

Cross-talk between NK cells and dendritic cells (DCs) is critical for the potent therapeutic response to dsRNA, but the receptors involved remained controversial. We show in this paper that two dsRNAs, polyadenylic-polyuridylic acid and polyinosinic-polycytidylic acid [poly(I:C)], similarly engaged human TLR3, whereas only poly(I:C) triggered human RIG-I and MDA5. Both dsRNA enhanced NK cell activation within PBMCs but only poly(I:C) induced IFN-gamma. Although myeloid DCs (mDCs) were required for NK cell activation, induction of cytolytic potential and IFN-gamma production did not require contact with mDCs but was dependent on type I IFN and IL-12, respectively. Poly(I:C) but not polyadenylic-polyuridylic acid synergized with mDC-derived IL-12 for IFN-gamma production by acting directly on NK cells. Finally, the requirement of both TLR3 and Rig-like receptor (RLR) on mDCs and RLRs but not TLR3 on NK cells for IFN-gamma production was demonstrated using TLR3- and Cardif-deficient mice and human RIG-I-specific activator. Thus, we report the requirement of cotriggering TLR3 and RLR on mDCs and RLRs on NK cells for a pathogen product to induce potent innate cell activation.

Safety of human immunisation with a live-attenuated Mycobacterium tuberculosis vaccine: a randomised, double-blind, controlled phase I trial.

BACKGROUND: Tuberculosis remains one of the world's deadliest transmissible diseases despite widespread use of the BCG vaccine. MTBVAC is a new live tuberculosis vaccine based on genetically attenuated Mycobacterium tuberculosis that expresses most antigens present in human isolates of M tuberculosis. We aimed to compare the safety of MTBVAC with BCG in healthy adult volunteers. METHODS: We did this single-centre, randomised, double-blind, controlled phase 1 study at the Centre Hospitalier Universitaire Vaudois (CHUV; Lausanne, Switzerland). Volunteers were eligible for inclusion if they were aged 18-45 years, clinically healthy, HIV-negative and tuberculosis-negative, and had no history of active tuberculosis, chemoprophylaxis for tuberculosis, or BCG vaccination. Volunteers fulfilling the inclusion criteria were randomly assigned to three cohorts in a dose-escalation manner. Randomisation was done centrally by the CHUV Pharmacy and treatments were masked from the study team and volunteers. As participants were recruited within each cohort, they were randomly assigned 3:1 to receive MTBVAC or BCG. Of the participants allocated MTBVAC, those in the first cohort received 5 × 10(3) colony forming units (CFU) MTBVAC, those in the second cohort received 5 × 10(4) CFU MTBVAC, and those in the third cohort received 5 × 10(5) CFU MTBVAC. In all cohorts, participants assigned to receive BCG were given 5 × 10(5) CFU BCG. Each participant received a single intradermal injection of their assigned vaccine in 0·1 mL sterile water in their non-dominant arm. The primary outcome was safety in all vaccinated participants. Secondary outcomes included whole blood cell-mediated immune response to live MTBVAC and BCG, and interferon γ release assays (IGRA) of peripheral blood mononuclear cells. This trial is registered with ClinicalTrials.gov, number NCT02013245. FINDINGS: Between Jan 23, 2013, and Nov 6, 2013, we enrolled 36 volunteers into three cohorts, each of which consisted of nine participants who received MTBVAC and three who received BCG. 34 volunteers completed the trial. The safety of vaccination with MTBVAC at all doses was similar to that of BCG, and vaccination did not induce any serious adverse events. All individuals were IGRA negative at the end of follow-up (day 210). After whole blood stimulation with live MTBVAC or BCG, MTBVAC was at least as immunogenic as BCG. At the same dose as BCG (5×10(5) CFU), although no statistical significance could be achieved, there were more responders in the MTBVAC group than in the BCG group, with a greater frequency of polyfunctional CD4+ central memory T cells. INTERPRETATION: To our knowledge, MTBVAC is the first live-attenuated M tuberculosis vaccine to reach clinical assessment, showing similar safety to BCG. MTBVAC seemed to be at least as immunogenic as BCG, but the study was not powered to investigate this outcome. Further plans to use more immunogenicity endpoints in a larger number of volunteers (adults and adolescents) are underway, with the aim to thoroughly characterise and potentially distinguish immunogenicity between MTBVAC and BCG in tuberculosis-endemic countries. Combined with an excellent safety profile, these data support advanced clinical development in high-burden tuberculosis endemic countries. FUNDING: Biofabri and Bill & Melinda Gates Foundation through the TuBerculosis Vaccine Initiative (TBVI).

Development and evaluation of double locus sequence typing for molecular epidemiological investigations of Clostridium difficile.

Despite the development of novel typing methods based on whole genome sequencing, most laboratories still rely on classical molecular methods for outbreak investigation or surveillance. Reference methods for Clostridium difficile include ribotyping and pulsed-field gel electrophoresis, which are band-comparing methods often difficult to establish and which require reference strain collections. Here, we present the double locus sequence typing (DLST) scheme as a tool to analyse C. difficile isolates. Using a collection of clinical C. difficile isolates recovered during a 1-year period, we evaluated the performance of DLST and compared the results to multilocus sequence typing (MLST), a sequence-based method that has been used to study the structure of bacterial populations and highlight major clones. DLST had a higher discriminatory power compared to MLST (Simpson's index of diversity of 0.979 versus 0.965) and successfully identified all isolates of the study (100 % typeability). Previous studies showed that the discriminatory power of ribotyping was comparable to that of MLST; thus, DLST might be more discriminatory than ribotyping. DLST is easy to establish and provides several advantages, including absence of DNA extraction [polymerase chain reaction (PCR) is performed on colonies], no specific instrumentation, low cost and unambiguous definition of types. Moreover, the implementation of a DLST typing scheme on an Internet database, such as that previously done for Staphylococcus aureus and Pseudomonas aeruginosa ( http://www.dlst.org ), will allow users to easily obtain the DLST type by submitting directly sequencing files and will avoid problems associated with multiple databases.

Double formule d'une lettre d'indulgences datée de l'année 1539 et émanée du maître, des frères et des gouverneurs de l'hôpital Saint-Louis des Quinze-Vingt de Paris

[Acte. 1539]

Melle Fondarana [i. e. Isabel Fonrodona], M. [Manuel] Alonso [vainqueurs du double mixte au championnat du monde de tennis à Saint-Cloud] : [photographie de presse] / [Agence Rol]

Référence bibliographique : Rol, 59417

30/5/20, finale du championnat [du monde] double entre Gobert - Laurentz et [Blackbeard - Mishu] : [photographie de presse] / [Agence Rol]

Référence bibliographique : Rol, 59455

30/5/20, finale du championnat [du monde] double entre Gobert - Laurentz et [Blackbeard-Mishu] : [photographie de presse] / [Agence Rol]

Référence bibliographique : Rol, 59456

Saint-Cloud, 24/05/20, Mme [Marie] Danet, Mlle [Marie] Conquet [double-dames du Championnat du monde de Tennis] : [photographie de presse] / [Agence Rol]

Référence bibliographique : Rol, 59399

Saint-Cloud, 23/5/20, Mlle Amblard-Decugis contre Mme Speranza-Shimidzu [double-mixte de tennis au Championnat du monde] : [photographie de presse] / [Agence Rol]

Référence bibliographique : Rol, 59402

Saint-Cloud, 24/5/20, Mme Danet et Mlle Conquet [double-dames de tennis au Championnat du monde] : [photographie de presse] / [Agence Rol]

Référence bibliographique : Rol, 59403

Mlle Subirana et Mlle Fondarana [i. e. Isabel Fonrodona, portrait des 2 joueuses du double-dames de tennis au Championnat du monde, à Saint-Cloud] : [photographie de presse] / [Agence Rol]

Référence bibliographique : Rol, 59404

Miss Hollman [i. e. Dorothy Holman], 30-5-20 [finale double dames du championnat du monde à Saint-Cloud avec Mrs Satterthwaite] : [photographie de presse] / [Agence Rol]

Référence bibliographique : Rol, 59468

Miss Hollman [i. e. Dorothy Holman], 30-5-20 [finale double dames du championnat du monde à Saint-Cloud avec Mrs Satterthwaite] : [photographie de presse] / [Agence Rol]

Référence bibliographique : Rol, 59469

10-6-20, championnats de France [de] tennis, Miss Lenglen [associée en double à Mlle d'Ayen, courts de la Croix-Catelan] : [photographie de presse] / [Agence Rol]

Référence bibliographique : Rol, 59628

10-6-20, championnats de France [de] tennis, Miss Lenglen [associée en double à Mlle d'Ayen, courts de la Croix-Catelan] : [photographie de presse] / [Agence Rol]

Référence bibliographique : Rol, 59629